Orakl Oncology
Building the first truly native [AIxBio] engine; its proprietary dataset teaches AI to decode biology and predict how patients respond to new drugs orakl-oncology.com
Funding
- $34 million Series A, announced November 12, 2026. Led by Norrsken VC and Singular. European Biotechnology also gives the amount as €31 million. Listed in the AI startup funding roster for November 8–14, 2026. Sources: European Biotechnology, Tech Funding News.
Of the 90 Series A rounds with exactly stated amounts in dollars on Presspool's weekly rosters since September 21, 2026, Orakl Oncology's $34 million is the joint 23rd largest; their median is $20.85 million.
Whether AI names Orakl Oncology
- Machine Relations Index: Not cited in any Machine Relations Index answer, May 10, 2026 to November 14, 2026.
Related records
Closest rounds in the roster for November 8–14, 2026: Graphon Labs ($35 million Series A, November 10, 2026), Bay ($37 million Series A, November 10, 2026), SE3 ($30 million Series A, November 12, 2026), Luminal ($25 million Series A, November 12, 2026), Lumbra ($25 million Series A, November 10, 2026), Hatz AI ($24 million Series A, November 12, 2026).
Norrsken VC, which led this round, also led Vocca ($20 million Series A, October 5, 2026).
Singular, which led this round, also led Sumary ($25m Seed, November 9, 2026) and Restate ($20 million Series A, September 30, 2026).